Viewing Study NCT02990247


Ignite Creation Date: 2025-12-18 @ 9:24 AM
Ignite Modification Date: 2025-12-18 @ 9:24 AM
Study NCT ID: NCT02990247
Status: None
Last Update Posted: 2018-12-13 00:00:00
First Post: 2016-12-02 00:00:00
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Home Telemonitoring of Resting Spontaneous Breathing in Severe Asthma: a Pilot Study
Sponsor: None
Organization:

Study Overview

Official Title: Home Telemonitoring of Resting Spontaneous Breathing in Severe Asthma: a Pilot Study
Status: None
Status Verified Date: 2018-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: AsthmaDom
Brief Summary: Asthma exacerbations represent an acute or sub-acute worsening in symptoms and lung function from the patient's usual status. Early detection of exacerbations is a major public health issue. In clinic, management of asthma involves asthma control questionnaires and pulmonary function tests (Forced Expiratory Volume (FEV1), Fractional exhaled nitric oxide or FeNO). At home, the peak expiratory flow rate (PEFR) measured by the peak flow meter is an aid to monitor asthma but its ability to predict asthma exacerbations remains controversial. Anharmonic morphological analysis of the respiratory signals (AMARS) is a new morpho-mathematic biomarker that produces objective and accurate measures of the shape of the ventilatory flow. The current study aims at monitoring the resting spontaneous breathing at home in asthmatics. Changes in AMARS may be a predictor of early symptoms of asthma exacerbations. We will recruit 120 asthmatic patients. Patients will be given a portable device for telemonitoring. Resting spontaneous breathing will be measured during 2-3 min in the morning and in the evening, twice a week at least for 12 months. Three visits will be scheduled in Clinical Investigation Center before (V1), after 6-month (V2) and 12-month (V3) telemonitoring period.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: